EV-to-FCF is calculated as enterprise value divided by its free cash flow. As of today, Johnson & Johnson's Enterprise Value is $407,345 Mil.
Johnson & Johnson's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 was $18,574 Mil. Therefore, Johnson & Johnson's EV-to-FCF for today is 21.93.
The historical rank and industry rank for Johnson & Johnson's EV-to-FCF or its related term are showing as below:
JNJ'
s EV-to-FCF Range Over the Past 10 Years
Min: 15.67 Med: 21.25 Max: 32.76
Current: 21.93
During the past 13 years, the highest EV-to-FCF of Johnson & Johnson was 32.76. The lowest was 15.67. And the median was 21.25.
JNJ's EV-to-FCF is ranked better than 55.14% of 535
companies
in the Drug Manufacturers industry
Industry Median: 25.85
vs JNJ: 21.93
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
The historical data trend for Johnson & Johnson's EV-to-FCF can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Competitive Comparison of Johnson & Johnson's EV-to-FCF
For the Drug Manufacturers - General subindustry, Johnson & Johnson's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Johnson & Johnson's EV-to-FCF Distribution in the Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Johnson & Johnson's EV-to-FCF distribution charts can be found below:
* The bar in red indicates where Johnson & Johnson's EV-to-FCF falls into.
Johnson & Johnson's current Enterprise Value is $407,345 Mil.
Johnson & Johnson's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $18,574 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Johnson & Johnson (NYSE:JNJ) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
Johnson & Johnson's PE Ratio (TTM) for today is calculated as:
Johnson & Johnson's share price for today is $163.70.
Johnson & Johnson's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.350.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
Johnson & Johnson EV-to-FCF Related Terms
Thank you for viewing the detailed overview of Johnson & Johnson's EV-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: pharmaceutical and medical devices. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. The drug division focuses on the following therapeutic areas: immunology, oncology, neurology, pulmonary, cardiology, and metabolic diseases. Geographically, just over half of total revenue is generated in the United States.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
JNJ has been successfully added to your 